Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454505 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AL-53817 Nasal Spray Solution
A Phase 1 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT01454505: Completed Phase 1 study, sponsored by Alcon Research.
NCT01454505 is a Phase 1 study that has completed, run by Alcon Research. The registered enrollment target is 110 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01454505, a Phase 1 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
Primary Outcome
Adverse events, including serious adverse events and deaths, were reported regardless of test article relationship.
Interventions
- DRUG AL-53817 nasal spray solution
- OTHER Vehicle nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT01454505 record still lists
NCT01454505 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% higher).
The record links to 0 conditions, and to 2 interventions - of which AL-53817 nasal spray solution is the first listed.
NCT01454505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01454505 about?
NCT01454505 is a clinical study titled "Safety and Efficacy of AL-53817 Nasal Spray Solution". The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
What is the current status of trial NCT01454505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2011-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01454505?
The interventions under investigation include: AL-53817 nasal spray solution (DRUG), Vehicle nasal spray (OTHER).
Who is sponsoring clinical trial NCT01454505?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01454505's enrollment target sits among peer trials
110 514th of 2000 higher than 1,479 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia